drugset / Trial / NCT00537576

Safety Study of Lactobacillus Administered Vaginally to Healthy Women

NCT00537576

RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to compare the safety, tolerability, and acceptability of LACTIN-V (Active Ingredient: Lactobacillus crispatus CTV-05) with a matching placebo at three doses using pre-filled vaginal applicators in healthy pre-menopausal women. The study hypothesis is that LACTIN-V will be safe, tolerable, and acceptable at each dose and will not differ significantly from the placebo controls.

Timeline

Start
2007-11
Primary completion
2008-03
Completion
2008-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LACTIN-V Other / unclassified 150 mg Intravenous
Subject LACTIN-V Other / unclassified 300 mg Intravenous
Subject LACTIN-V Other / unclassified 600 mg Intravenous

Indications